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Derivatives of amphetamines are widely abused all over the world. After long-term use cognitive, 
neurophysiological, and neuroanatomical deficits have been reported. Neurophysiological deficits are enhanced by 
hyperthermia, which itself is major mortality factor in drug abusers. Temperature responses to injections of 
methamphetamine are multiphasic and include both hypothermic and hyperthermic phases, which are highly 
dependent on ambient temperature and previous exposure to the drug. Also, amphetamine derivatives differentially 
affect various neuromediator systems, such as dopaminergic, noradrenergic and serotonergic.  
Temperature responses to methamphetamine (Meth) at room temperature have non-trivial dose-dependence, 
which is far from being understood. Intermediate doses of Meth cause less hyperthermia than both low and high 
doses of the drug. Also, maxima of all responses have different latency responses to low and high doses are virtually 
immediate, while a response to an intermediate dose appears to be delayed. In our previous modeling study we 
demonstrated that such dose-dependence could be explained by interaction of inhibitory and excitatory drives 
induced by Meth [1]. Recently, we have published data on the involvement of orexinergic neurotransmission in 
Meth-induced temperature responses [2] where the low dose (10 mg/kg, i.p.) of SB-334867 (SB), an antagonist of 
the first type of orexin receptors (ORX1), was injected 30 min prior to various doses of Meth. While this dose of 
antagonist clearly suppressed the response to low (1 mg/kg) and intermediate (5 mg/kg) doses of Meth, the effect 
was statistically significant only at the late phase (t > 60 min) of the response to intermediate dose. At the early 
phase (t < 60 min) any drug-related changes were marred by stress-induced temperature fluctuations resulting from 
two intraperitoneal injections. In a separate set of experiments a high dose of the same antagonist (30 mg/kg, i.p.) 
suppressed the effect of low doses of Meth even more, but in contrast, it significantly amplified the responses to the 
higher doses (5 and 10 mg/kg) of Meth.  
Understanding the mechanism that differentially affect excitatory and inhibitory components of temperature 
responses can have profound importance for explaining cases of life-threatening hyperthermia after Meth 
administration. Therefore, we performed a mathematical modeling study to provide mechanistic interpretation of SB 
action. Our previous model [1] was created to describe Meth-sensitive compartments and dynamics of the neural 
populations defining temperature responses for various doses of Meth. We hypothesized that a specific distribution 
of orexin receptors over the structures involved in the neural control of temperature is responsible for the complex 
dependence of the Meth-induced responses on the dose of orexin antagonist. To test this hypothesis we extended the 
model by  incorporating ORX receptors that mediated Meth- and stress-dependent inputs. We showed that the low 
dose of antagonist almost fully suppresses the responses to both stress and intermediate doses of Meth by disruption 
of the corresponding inputs to the control structures. This allows hypothesizing that the excitatory component in 
temperature response to both stress and low dose of Meth is mediated by ORX1 receptors. Amplification of the 
response to the high dose of Meth at high dose of the antagonist points out to the involvement of a mechanism 
different from ORX1  receptor blockade. We speculate that at high doses SB becomes non-specific to ORX1 
receptors and starts affecting ORX2 receptors. Further, ORX2 activation disinhibits the structure activated by high 
doses of Meth, which underlies the exaggerated responses to high doses of Meth at the presence of a high dose of 
SB.  We conclude that both excitatory and inhibitory components in temperature responses to Meth administration 
and stress are mediated by orexinergic pathways. Non-specificity of SB at high doses to ORX1 receptors manifests 
itself in additional suppression of inhibition resulting in facilitation of the responses to high-doses of Meth. 
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